Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 42.47 Billion KRW | 59.44% |
| 2022 | 26.63 Billion KRW | 48.55% |
| 2021 | 17.93 Billion KRW | 18.52% |
| 2020 | 15.12 Billion KRW | -22.1% |
| 2019 | 19.42 Billion KRW | -4.49% |
| 2018 | 20.33 Billion KRW | -14.03% |
| 2017 | 23.65 Billion KRW | 4.96% |
| 2016 | 22.53 Billion KRW | 15.14% |
| 2015 | 19.57 Billion KRW | 3.61% |
| 2014 | 18.88 Billion KRW | -4.16% |
| 2013 | 19.71 Billion KRW | -1.19% |
| 2012 | 19.94 Billion KRW | -1.37% |
| 2011 | 20.22 Billion KRW | 1.02% |
| 2010 | 20.01 Billion KRW | 7.44% |
| 2009 | 18.63 Billion KRW | -0.85% |
| 2008 | 18.79 Billion KRW | -11.99% |
| 2007 | 21.35 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 9.19 Billion KRW | -6.1% |
| 2024 Q2 | 8.79 Billion KRW | -4.35% |
| 2023 FY | 42.47 Billion KRW | 59.44% |
| 2023 Q1 | 11.86 Billion KRW | 75.63% |
| 2023 Q4 | 9.78 Billion KRW | 208.93% |
| 2023 Q3 | -8.98 Billion KRW | 32.94% |
| 2023 Q2 | -13.4 Billion KRW | -212.95% |
| 2022 Q1 | 5.82 Billion KRW | 9.32% |
| 2022 Q3 | 6.7 Billion KRW | -8.89% |
| 2022 Q4 | 6.75 Billion KRW | 0.77% |
| 2022 Q2 | 7.35 Billion KRW | 26.38% |
| 2022 FY | 26.63 Billion KRW | 48.55% |
| 2021 Q4 | 5.32 Billion KRW | 16.82% |
| 2021 FY | 17.93 Billion KRW | 18.52% |
| 2021 Q1 | 3.69 Billion KRW | -4.29% |
| 2021 Q2 | 4.34 Billion KRW | 17.58% |
| 2021 Q3 | 4.55 Billion KRW | 4.81% |
| 2020 Q1 | 4.15 Billion KRW | -17.61% |
| 2020 Q3 | 3.52 Billion KRW | -1.59% |
| 2020 Q2 | 3.58 Billion KRW | -13.64% |
| 2020 FY | 15.12 Billion KRW | -22.1% |
| 2020 Q4 | 3.86 Billion KRW | 9.54% |
| 2019 Q3 | 4.66 Billion KRW | -1.79% |
| 2019 FY | 19.42 Billion KRW | -4.49% |
| 2019 Q1 | 4.96 Billion KRW | -6.84% |
| 2019 Q4 | 5.03 Billion KRW | 8.0% |
| 2019 Q2 | 4.75 Billion KRW | -4.35% |
| 2018 Q2 | 5.36 Billion KRW | 11.37% |
| 2018 Q1 | 4.82 Billion KRW | -18.7% |
| 2018 FY | 20.33 Billion KRW | -14.03% |
| 2018 Q3 | 4.81 Billion KRW | -10.38% |
| 2018 Q4 | 5.33 Billion KRW | 10.79% |
| 2017 Q1 | 5.23 Billion KRW | -11.02% |
| 2017 Q4 | 5.93 Billion KRW | 2.87% |
| 2017 Q3 | 5.76 Billion KRW | -14.46% |
| 2017 Q2 | 6.73 Billion KRW | 28.83% |
| 2017 FY | 23.65 Billion KRW | 4.96% |
| 2016 Q1 | 5.06 Billion KRW | -5.47% |
| 2016 FY | 22.53 Billion KRW | 15.14% |
| 2016 Q4 | 5.88 Billion KRW | -7.07% |
| 2016 Q3 | 6.32 Billion KRW | 20.32% |
| 2016 Q2 | 5.25 Billion KRW | 3.74% |
| 2015 FY | 19.57 Billion KRW | 3.61% |
| 2015 Q4 | 5.36 Billion KRW | 13.2% |
| 2015 Q3 | 4.73 Billion KRW | 0.61% |
| 2015 Q2 | 4.7 Billion KRW | -1.15% |
| 2015 Q1 | 4.76 Billion KRW | -3.05% |
| 2014 FY | 18.88 Billion KRW | -4.16% |
| 2014 Q1 | 4.89 Billion KRW | -5.84% |
| 2014 Q4 | 4.91 Billion KRW | 15.23% |
| 2014 Q3 | 4.26 Billion KRW | -11.57% |
| 2014 Q2 | 4.82 Billion KRW | -1.41% |
| 2013 Q3 | 4.6 Billion KRW | -1.8% |
| 2013 Q4 | 5.19 Billion KRW | 12.76% |
| 2013 FY | 19.71 Billion KRW | -1.19% |
| 2013 Q1 | 5.21 Billion KRW | -5.25% |
| 2013 Q2 | 4.69 Billion KRW | -10.11% |
| 2012 Q4 | 5.5 Billion KRW | 17.1% |
| 2012 Q2 | 5.02 Billion KRW | 6.79% |
| 2012 FY | 19.94 Billion KRW | -1.37% |
| 2012 Q3 | 4.7 Billion KRW | -6.45% |
| 2012 Q1 | 4.7 Billion KRW | -14.34% |
| 2011 Q4 | 5.49 Billion KRW | 9.67% |
| 2011 Q1 | 4.64 Billion KRW | -10.55% |
| 2011 Q2 | 5.06 Billion KRW | 9.01% |
| 2011 FY | 20.22 Billion KRW | 1.02% |
| 2011 Q3 | 5.01 Billion KRW | -1.12% |
| 2010 FY | 20.01 Billion KRW | 7.44% |
| 2010 Q4 | 5.19 Billion KRW | 8.71% |
| 2010 Q3 | 4.78 Billion KRW | -3.99% |
| 2010 Q2 | 4.97 Billion KRW | -1.66% |
| 2010 Q1 | 5.06 Billion KRW | -2.2% |
| 2009 Q2 | 4.7 Billion KRW | 10.83% |
| 2009 Q3 | 4.51 Billion KRW | -4.2% |
| 2009 Q1 | 4.24 Billion KRW | -11.4% |
| 2009 Q4 | 5.17 Billion KRW | 14.75% |
| 2009 FY | 18.63 Billion KRW | -0.85% |
| 2008 Q4 | 4.79 Billion KRW | 6.77% |
| 2008 Q3 | 4.49 Billion KRW | -6.14% |
| 2008 Q2 | 4.78 Billion KRW | 1.38% |
| 2008 Q1 | 4.72 Billion KRW | -20.72% |
| 2008 FY | 18.79 Billion KRW | -11.99% |
| 2007 FY | 21.35 Billion KRW | 0.0% |
| 2007 Q4 | 5.95 Billion KRW | 21.71% |
| 2007 Q3 | 4.89 Billion KRW | -11.62% |
| 2007 Q2 | 5.53 Billion KRW | 10.17% |
| 2007 Q1 | 5.02 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 10.12% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 85.747% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 84.746% |
| HANDOK Inc. | 153.76 Billion KRW | 72.379% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 38.637% |
| Yuhan Corporation | 489.94 Billion KRW | 91.331% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 86.164% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -1.633% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 93.048% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 40.998% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 75.612% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -6.039% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 54.601% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 62.98% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 10.12% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 43.408% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | 27.577% |
| JW Holdings Corporation | 301.25 Billion KRW | 85.902% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 83.725% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 89.607% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 82.223% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 66.733% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 37.826% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | 35.406% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 75.72% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 10.12% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 82.951% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 92.422% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 82.223% |
| Yuhan Corporation | 489.94 Billion KRW | 91.331% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 78.069% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 38.862% |
| Suheung Co., Ltd. | 56.03 Billion KRW | 24.201% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 82.223% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 66.397% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 64.072% |
| CKD Bio Corp. | 25.19 Billion KRW | -68.567% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 80.868% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 74.277% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 36.053% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 66.733% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 87.89% |
| Boryung Corporation | 285.16 Billion KRW | 85.106% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 51.484% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 75.612% |
| JW Lifescience Corporation | 20.26 Billion KRW | -109.617% |